Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 73 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Palliative Radiotherapy Clear all
Completed Phase 2Phase 3 Interventional Results available

A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms

NCT02163226
View directory record Official record
Conditions
Bone Metastases
Interventions
Hypofractionated Radiation Treatment, One Radiation Treatment, Questionnaire
Radiation · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Gilbert, Arizona • Voorhees Township, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Sep 2, 2026, 7:15 AM EDT
Completed Phase 1 Interventional

Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients

NCT05002140
View directory record Official record
Conditions
Metastasis, Locally Advanced Solid Tumor, Recurrent Cancer
Interventions
XRD-0394, Palliative radiotherapy
Drug · Radiation
Lead sponsor
XRad Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Stanford, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Sep 2, 2026, 7:15 AM EDT
Terminated Phase 1 Interventional Results available

M3541 in Combination With Radiotherapy in Solid Tumors

NCT03225105
View directory record Official record
Conditions
Solid Tumors
Interventions
M3541, Palliative Radiotherapy (RT)
Drug · Radiation
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Indianapolis, Indiana • St Louis, Missouri • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 2, 2026, 7:15 AM EDT
Completed Phase 2 Interventional Results available

Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma

NCT01781728
View directory record Official record
Conditions
Pancreatic Cancer, Periampullary Adenocarcinoma
Interventions
Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 2, 2026, 7:15 AM EDT
Withdrawn Not applicable Interventional

MR Guided Focused Ultrasound vs Radiotherapy for Palliative Pain Tx in Bone Metastases

NCT05250687
View directory record Official record
Conditions
Bone Metastases
Interventions
MR- High intensity focused ultrasound, External beam radiotherapy
Procedure · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 2, 2026, 7:15 AM EDT
Completed Not applicable Interventional Results available

ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain

NCT00656305
View directory record Official record
Conditions
Bone Metastases, Multiple Myeloma
Interventions
ExAblate MRfFUS, Sham
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years to 100 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
8
States / cities
La Jolla, California • Stanford, California • Boca Raton, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 2, 2026, 7:15 AM EDT
Recruiting Phase 2 Interventional

Hybrid Arc Palliative Radiation Therapy (HART): A Single Arm Phase II Trial

NCT06778408
View directory record Official record
Conditions
Palliative Radiotherapy, Metastatic Cancer (Different Solid Tumour Types)
Interventions
Hybrid Palliative Radiation Therapy
Radiation
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 2, 2026, 7:15 AM EDT
Completed Not applicable Interventional Results available

Mindfulness Therapy for Individuals With Lung Cancer

NCT01565980
View directory record Official record
Conditions
Lung Cancer
Interventions
symptom assessment, Mindfulness Intervention
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Chicago, Illinois • East Lansing, Michigan • Jackson, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 16, 2014 · Synced Sep 2, 2026, 7:15 AM EDT
Completed Phase 2 Interventional Results available

Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy

NCT01449279
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 2, 2026, 7:15 AM EDT
Completed Phase 1 Interventional

3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Recurrent Tumors

NCT01470365
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
quality-of-life assessment, intensity-modulated radiation therapy, 3-dimensional conformal radiation therapy
Procedure · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Sep 2, 2026, 7:15 AM EDT
Recruiting Phase 2 Interventional

3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial

NCT05674396
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Stereotactic body radiotherapy, Traditional Palliation
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 2, 2026, 7:15 AM EDT
Recruiting No phase listed Observational

A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated With Percutaneous Ablation and Palliative Radiation Therapy

NCT06859801
View directory record Official record
Conditions
Bone Cancer Metastatic
Interventions
Percutaneous Ablation, Radiation Therapy
Device · Radiation
Lead sponsor
Society of Interventional Oncology
Other
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 2, 2026, 7:15 AM EDT
Completed Not applicable Interventional Results available

Default Options to Reduce Unnecessary Daily Imaging During Palliative Radiation

NCT03110692
View directory record Official record
Conditions
Cancer
Interventions
Default initiation
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1,188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 2, 2026, 7:15 AM EDT
Terminated Phase 2 Interventional Results available

Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC

NCT03051672
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Pembrolizumab, Palliative radiotherapy
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Sep 2, 2026, 7:15 AM EDT
Not listed Phase 2 Interventional

Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy

NCT00003856
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
temoporfin
Drug
Lead sponsor
Quintiles, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
7
States / cities
Little Rock, Arkansas • Tampa, Florida • Evanston, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 2, 2026, 7:15 AM EDT
Completed Phase 1 Interventional

Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer

NCT01652794
View directory record Official record
Conditions
Leydig Cell Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Pseudomyxoma Peritonei, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer, Recurrent Uterine Sarcoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer
Interventions
stereotactic body radiation therapy, carboplatin, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacogenomic studies
Radiation · Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Sep 2, 2026, 7:15 AM EDT
Completed Phase 2 Interventional Results available

Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy

NCT03007407
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
durvalumab, Tremelimumab
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
18
States / cities
Duarte, California • New Haven, Connecticut • North Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2022 · Synced Sep 2, 2026, 7:15 AM EDT
Withdrawn Phase 1 Interventional

Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation

NCT02159248
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Tolfenamic acid + gemcitabine + radiation
Drug
Lead sponsor
Orlando Health, Inc.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Sep 2, 2026, 7:15 AM EDT
Completed Not applicable Interventional Results available

Image-Guided Navigation for High Dose Rate Temporary Interstitial Brachytherapy in the Palliative Management of Previously Treated Tumors of the Spine and Pelvis

NCT01757717
View directory record Official record
Conditions
Metastatic or Recurrent Lesions in the Spine, Metastatic or Recurrent Lesions in the Pelvis
Interventions
Ir-192 high dose rate (HDR)
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Sep 2, 2026, 7:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Saw Palmetto: Symptom Management for Men During Radiation Therapy

NCT01585246
View directory record Official record
Conditions
Prostate Cancer
Interventions
Saw Palmetto, soybean oil soft gel
Drug
Lead sponsor
Michigan State University
Other
Eligibility
21 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
6
States / cities
Jackson, Michigan • Lansing, Michigan • Mount Clemens, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Sep 2, 2026, 7:15 AM EDT
Active, not recruiting Phase 2 Interventional

"QUAD SHOT" Radiotherapy With Pembrolizumab in Patients With Recurrent Head & Neck Cancer

NCT04373642
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Pebrolizumab + QUADSHOT Radiotherapy
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 2, 2026, 7:15 AM EDT
Completed Phase 1 Interventional Results available

NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy

NCT02319824
View directory record Official record
Conditions
Sarcoma
Interventions
Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Laboratory Biomarker Analysis, Palliative Radiation Therapy
Biological · Other · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 4, 2017 · Synced Sep 2, 2026, 7:15 AM EDT
Recruiting Phase 2 Interventional

Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer

NCT04990921
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Palliative Radiation and Pembrolizumab
Combination Product
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 2, 2026, 7:15 AM EDT
Active, not recruiting Early Phase 1 Interventional

Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma

NCT06308913
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
INCB081776, Pembrolizumab, Palliative RT
Drug · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 2, 2026, 7:15 AM EDT